Quanterix Wins China NMPA Approval for SIMOA Instruments and Four Alzheimer's Biomarker Tests
QTRX sits 60% above its 52-week low of $2.15.
Summary
Quanterix and partner Innovita received NMPA approval in China for the HD-X and SR-X instruments plus four neurology biomarker kits: p-Tau 217, GFAP, p-Tau 181, and NfL. This opens the large Chinese IVD market to Quanterix's ultra-sensitive SIMOA technology for Alzheimer's testing. The approval follows Quanterix's Q2 revenue miss and guidance cut in August, making this a meaningful positive development for the company's growth story. Innovita plans additional regulatory submissions, potentially expanding into other neurodegenerative and infectious diseases.
At the time of this announcement, QTRX was trading at $3.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $162.7M. The 52-week trading range was $2.15 to $8.77. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.